Blue Jet Healthcare Ltd (BLUEJET) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Blue Jet Healthcare achieved record-setting performance in FY25 with significant progress across operational and financial metrics.
- Revenue growth was accompanied by improved earnings quality due to new capacity additions, operational leverage, and cost control.
- FY25 revenue reached Rs. 10,300 million, a 45% year-on-year increase. EBITDA was Rs. 3,777 million with a 37% margin, up 65% year-on-year. PAT reached Rs. 3,052 million, an 87% year-on-year increase.
- Q4 FY25 revenue was Rs. 3,404 million, up 7% quarter-on-quarter and 85% year-on-year. EBITDA was Rs. 1,400 million with a 41% margin, up from 39% in Q3 and 29% in Q4 of the previous year.
- The company remains debt-free and declared a dividend of Rs. 1.20 per share, subject to shareholder approval.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.